| CASE REPORT |
|
| Year : 2021 | Volume
: 5
| Issue : 1 | Page : 31-33 |
|
|
Postintravenous immunoglobulins posterior reversible encephalopathy syndrome in a patient with miller fisher variant of guillain–barre syndrome: A case report and literature review
Ans Alamami1, Rabee Tawel1, Farah Zahra2, Mohamed Abelaty1
1 Department of Critical Care, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
2 Department of Pharmacy, Alwakra Hospital, Hamad Medical Corporation, Doha, Qatar
Correspondence Address:
Dr. Ans Alamami
P.O. Box 3050, Al Rayan Street, Doha
Qatar
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/LJMS.LJMS_103_20
|
|
|
Guillain–Barre syndrome (GBS) is an autoimmune disorder of the peripheral nerves manifested as inflammatory polyneuropathy of acute onset. The posterior reversible encephalopathy syndrome (PRES) is composed of gradual-onset neurological characteristics with unique radiological distribution (at the posterior brain region). Several etiologies, including hypertension, renal insufficiency, autoimmune diseases, medication use, and immunodeficiency, immunotherapy with intravenous immunoglobulin (IVIG) for various immune-related conditions, were associated with renal impairment, thrombotic manifestation, and reported PRES occurrence. Herein, we report a 73-year-old male who developed a clinical manifestation of PRES on top of IVIG therapy for Miller Fisher variant of GBS; therefore, PRES to be considered in a patient with GBS who treated with IVIG and developed alteration in the state of consciousness.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
